Literature DB >> 19690147

Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation.

Suzanne C Brady1, Mathew L Coleman, June Munro, Stephan M Feller, Nicolas A Morrice, Michael F Olson.   

Abstract

Sprouty2 is a feedback regulator that controls the Ras/Raf/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase (MAPK) pathway at multiple levels, one way being through direct interaction with Raf kinases. Consistent with a role as a tumor suppressor, Sprouty2 expression is often down-regulated in human cancers. However, Sprouty2 is up-regulated in some cancers, suggesting the existence of posttranscriptional mechanisms that permit evasion of Sprouty2-mediated antitumorigenic properties. We report that MAPK activation induces Sprouty2 phosphorylation on six serine residues, which reduced Sprouty2 association with wild-type B-Raf. Mutation of these six serines to nonphosphorylatable alanines increased the ability of Sprouty2 to inhibit growth factor-induced MAPK activation. Oncogenic B-Raf mutants such as B-Raf V600E did not associate with Sprouty2, but this resistance to Sprouty2 binding was not due to phosphorylation. Instead, the active kinase conformation induced by oncogenic mutation prevents Sprouty2 binding. These results reveal a dual mechanism that affects the Sprouty2/B-Raf interaction: Sprouty phosphorylation and B-Raf conformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690147      PMCID: PMC2762204          DOI: 10.1158/0008-5472.CAN-08-4447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling.

Authors:  Jacqueline M Mason; Debra J Morrison; M Albert Basson; Jonathan D Licht
Journal:  Trends Cell Biol       Date:  2005-12-07       Impact factor: 20.808

2.  The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation.

Authors:  Francis Edwin; Rakesh Singh; Raelene Endersby; Suzanne J Baker; Tarun B Patel
Journal:  J Biol Chem       Date:  2005-12-21       Impact factor: 5.157

3.  ERK pathway positively regulates the expression of Sprouty genes.

Authors:  K Ozaki; R Kadomoto; K Asato; S Tanimura; N Itoh; M Kohno
Journal:  Biochem Biophys Res Commun       Date:  2001-08-03       Impact factor: 3.575

4.  Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer.

Authors:  Arthur B McKie; David A Douglas; Sharon Olijslagers; Julia Graham; Mahmoud M Omar; Rakesh Heer; Vincent J Gnanapragasam; Craig N Robson; Hing Y Leung
Journal:  Oncogene       Date:  2005-03-24       Impact factor: 9.867

5.  Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis.

Authors:  J D Tefft; M Lee; S Smith; M Leinwand; J Zhao; P Bringas; D L Crowe; D Warburton
Journal:  Curr Biol       Date:  1999-02-25       Impact factor: 10.834

6.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.

Authors:  Atsuo Sasaki; Takaharu Taketomi; Reiko Kato; Kazuko Saeki; Atsushi Nonami; Mika Sasaki; Masamitsu Kuriyama; Naoaki Saito; Masabumi Shibuya; Akihiko Yoshimura
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

8.  Regulation of ERK activity duration by Sprouty contributes to dorsoventral patterning.

Authors:  Hiroshi Hanafusa; Kunihiro Matsumoto; Eisuke Nishida
Journal:  Nat Cell Biol       Date:  2009-01       Impact factor: 28.824

9.  Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis.

Authors:  George Minowada; York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2008-07-17       Impact factor: 6.914

10.  Sprouty is a general inhibitor of receptor tyrosine kinase signaling.

Authors:  A Reich; A Sapir; B Shilo
Journal:  Development       Date:  1999-09       Impact factor: 6.868

View more
  16 in total

1.  Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins.

Authors:  Kimberly Anderson; Kyle A Nordquist; Xianlong Gao; Kristin C Hicks; Bo Zhai; Steven P Gygi; Tarun B Patel
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

2.  Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.

Authors:  Jin Sun Kim; Gwang Hyeon Choi; Yusun Jung; Kang Mo Kim; Se-Jin Jang; Eun Sil Yu; Han Chu Lee
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-01       Impact factor: 4.553

Review 3.  Towards a molecular understanding of the differential signals regulating alphabeta/gammadelta T lineage choice.

Authors:  Sang-Yun Lee; Jason Stadanlick; Dietmar J Kappes; David L Wiest
Journal:  Semin Immunol       Date:  2010-05-14       Impact factor: 11.130

Review 4.  Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

Authors:  Christine A Pratilas; David B Solit
Journal:  Clin Cancer Res       Date:  2010-05-14       Impact factor: 12.531

5.  Targeting oncogenic BRAF in human cancer.

Authors:  Christine A Pratilas; Feng Xing; David B Solit
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

6.  HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2.

Authors:  Francis Edwin; Kimberly Anderson; Tarun B Patel
Journal:  J Biol Chem       Date:  2009-10-28       Impact factor: 5.157

7.  A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.

Authors:  Annamaria Milillo; Francesca La Carpia; Stefano Costanzi; Vanessa D'Urbano; Maurizio Martini; Paola Lanuti; Gisella Vischini; Luigi M Larocca; Marco Marchisio; Sebastiano Miscia; Antonio Amoroso; Fiorella Gurrieri; Eugenio Sangiorgi
Journal:  Eur J Hum Genet       Date:  2015-03-18       Impact factor: 4.246

8.  Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition.

Authors:  Britta Diedrich; Kristoffer Tg Rigbolt; Michael Röring; Ricarda Herr; Stephanie Kaeser-Pebernard; Christine Gretzmeier; Robert F Murphy; Tilman Brummer; Jörn Dengjel
Journal:  EMBO J       Date:  2017-01-16       Impact factor: 11.598

9.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Authors:  Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

10.  Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.

Authors:  Linda A Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Dafna Bar-Sagi; Kepal N Patel
Journal:  Surgery       Date:  2013-10-02       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.